Kudo et al. [25] showed that the use of the anti-PD-1 antibody, nivolumab, in 65 chemotherapy-refractory ESCC patients showed promising activity, with a 17% objective response rate and a manageable safety profile. The gene discussed is PDCD1; the disease is esophageal squamous cell carcinoma.